Ropes & Gray represented Blackstone Life Sciences in its $250 million investment in Anagram Therapeutics, a clinical-stage private biopharmaceutical company dedicated to improving the lives of people living with exocrine pancreatic insufficiency due to cystic fibrosis, pancreatic cancer, and related disorders. The transaction was announced on May 7.
The Ropes & Gray team was led by life sciences transactions partner Rajarshi Banerjee and IP transactions partner Melissa Rones, and included life sciences transactions partner Michael Beauvais, antitrust partner Deidre Johnson and counsel Derek Yee, life sciences transactions counsel Michael Spera, and IP transactions counsel Ryan Murphey.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.